According to American Cancer Society stats, colorectal cancer is the leading cause of cancer-associated mortality in males, and it is a common cause of death for females under 50 years of age. It is estimated that approximately 150,000 United States individuals will be diagnosed with colorectal cancer in 2024. Hence, several drugs by leading companies in the healthcare industry are currently in the pipeline, intended to provide immediate and effective solutions to those affected.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to colorectal cancer are covered. Moreover, colorectal cancer collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Colorectal cancer treatment may vary based on the cancer stage and the patient’s overall health and preferences. Surgical procedures such as polypectomy, local excision, colon resection with anastomosis or colostomy can be advised to a patient, Neoadjuvant therapies include radiation or chemotherapy. In March 2024, the United States FDA approved Fruzaqla (fruquintinib), an anti-VEGF treatment-based targeted therapy for metastatic colorectal cancer. The drug works by blocking the blood supply to a tumor and is advised to individuals with prior chemotherapy and a different anti-VEGF treatment.
In June 2024, the US FDA granted accelerated approval to Bristol Myer Squibb’s KRAZATI ® (adagrasib). The drug is intended to be used as a targeted treatment for KRASG12C -mutated locally advanced or metastatic colorectal cancer.
The U.S. FDA also approved an oral chemotherapy drug LONSURF (trifluridine and tipiracil) to be used in combination with Avastin (bevacizumab). While LONSURF was originally approved in 2015 and Avastin received its approval in 2004, the combination of these two together inhibited cancer spreading. LONSURF prevents cancer cell replication whereas Avastin blocks blood supply to the tumor. Such approvals demonstrate a preference for using combination drugs in order to provide maximum efficacy to patients. Moreover, the regulatory landscape for colorectal cancer therapeutic drugs is also shifting towards a positive note as more drugs get swift approvals from the authorities.
The Colorectal Cancer Pipeline Report covers pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.
This product will be delivered within 3-5 business days.
Report Coverage
The Colorectal Cancer Drug Pipeline Report by the publisher gives comprehensive insights on the colorectal cancer drugs currently undergoing clinical trials. It covers various aspects related to the details for each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies . The colorectal cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on colorectal cancer.The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to colorectal cancer are covered. Moreover, colorectal cancer collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Colorectal Cancer Drug Pipeline Outlook
Colorectal cancer is a type of cancer affecting the colon (large intestine) or rectum. Changes in bowel movements, leading to constipation or diarrhea, blood in stool, sudden weight loss, prolonged gas pains, bloating and cramps are amongst common disease symptoms. It is diagnosed through digital rectal exams, fecal occult blood tests, and physical exams such as sigmoidoscopy, colonoscopy, or stool tests.Colorectal cancer treatment may vary based on the cancer stage and the patient’s overall health and preferences. Surgical procedures such as polypectomy, local excision, colon resection with anastomosis or colostomy can be advised to a patient, Neoadjuvant therapies include radiation or chemotherapy. In March 2024, the United States FDA approved Fruzaqla (fruquintinib), an anti-VEGF treatment-based targeted therapy for metastatic colorectal cancer. The drug works by blocking the blood supply to a tumor and is advised to individuals with prior chemotherapy and a different anti-VEGF treatment.
In June 2024, the US FDA granted accelerated approval to Bristol Myer Squibb’s KRAZATI ® (adagrasib). The drug is intended to be used as a targeted treatment for KRASG12C -mutated locally advanced or metastatic colorectal cancer.
The U.S. FDA also approved an oral chemotherapy drug LONSURF (trifluridine and tipiracil) to be used in combination with Avastin (bevacizumab). While LONSURF was originally approved in 2015 and Avastin received its approval in 2004, the combination of these two together inhibited cancer spreading. LONSURF prevents cancer cell replication whereas Avastin blocks blood supply to the tumor. Such approvals demonstrate a preference for using combination drugs in order to provide maximum efficacy to patients. Moreover, the regulatory landscape for colorectal cancer therapeutic drugs is also shifting towards a positive note as more drugs get swift approvals from the authorities.
The Colorectal Cancer Pipeline Report covers pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.
Colorectal Cancer - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of colorectal cancer drug candidates based on various segmentations such as:
By Phase
The colorectal cancer therapeutic assessment report covers 50+ drug analysis based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Route of Administration
The pipeline assessment report covers 50+ drug analysis based on the route of administration.- Oral
- Parenteral
- Others
Colorectal Cancer - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes in depth analysis of each drug across these phases. According to analysis, phase II trials cover a major share of the total clinical trials conducted, with approximately 2,400 plus drugs in the pipeline.Colorectal Cancer- Pipeline Assessment Segmentation, By Route of Administration
The route of administration categories covered under Colorectal Cancer pipeline analysis include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to analysis, the parenteral route holds a significant market share based on the route of administration.Colorectal Cancer Clinical Trials Assessment - Competitive Dynamics
The report for the colorectal cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pancreatic cancer clinical trials:- Takeda Pharmaceuticals International AG
- Eli Lilly and Company
- Immatics Biotechnologies GmbH
- Daiichi Sankyo Co., Ltd.
- Millennium Pharmaceuticals, Inc.
- Pfizer & Co., Inc.
- Bristol-Myers Squibb Company
Colorectal Cancer - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and colorectal cancer therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming colorectal cancer drug candidates.Tisotumab Vedotin - Seagen Inc.
Sponsored by Seagen Inc., Tisotumab Vedotin is being evaluated for its efficacy, safety, and tolerability for the treatment of several solid tumors including colorectal center. Currently, in an open-label phase 2 study, the drug evaluation is expected to be completed by November 2026.Tucatinib With Trastuzumab and TAS-102 - Academic and Community Cancer Research United
Combined with trastuzumab and TAS-102, tucatinib is in the phase 2 trial to investigate its efficacy against shrinking tumors in patients with HER2-positive colorectal cancer. It belongs to a kinase inhibitor drug class.A2B530 - A2 Biotherapeutics Inc.
A2B530 is a Tmod™ CAR T cell therapy being evaluated in EVEREST-1, a multi-centre, open-label study including adult subjects with recurrent unresectable, locally advanced, or metastatic colorectal cancer. The first phase of the trial emphasizes determining the safety and optimal dosage whereas phase 2 further evaluates the safety and efficacy of the drug.Reasons To Buy This Report
The Colorectal Cancer Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for colorectal cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into colorectal cancer collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.Key Questions Answered in the Colorectal Cancer - Pipeline Assessment Report
- Which companies/institutions are leading the colorectal cancer drug development?
- What is the efficacy and safety profile of colorectal cancer pipeline drugs?
- Which company is leading the colorectal cancer pipeline development activities?
- What is the current colorectal cancer commercial assessment?
- What are the opportunities and challenges present in the colorectal cancer drug pipeline landscape?
- What is the efficacy and safety profile of colorectal cancer pipeline drugs?
- Which company is conducting major trials for colorectal cancer drugs?
- Which companies/institutions are involved in colorectal cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in colorectal cancer?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Colorectal Cancer
4 Patient Profile
5 Colorectal Cancer: Epidemiology Snapshot
6 Colorectal Cancer: Market Dynamics
7 Colorectal Cancer: Key Facts Covered
8 Colorectal Cancer, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Colorectal Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Colorectal Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Colorectal Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Colorectal Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Colorectal Cancer, Key Drug Pipeline Companies
